Biolight Life Sciences 

BioLight Life Sciences Ltd. is an ophthalmic firm dedicated to discovering, developing, and bringing to market innovative products and pipeline candidates designed to tackle various eye-related ailments. Its portfolio and development pipeline include DiagnosTear's TeaRx, a diagnostic platform analyzing tear fluid components to identify frontal eye diseases, and Peripherex, offering solutions for both at-home and clinical diagnosis and monitoring of peripheral vision loss, crucial for conditions like glaucoma. For glaucoma, BioLight features ViSci (an Eye D technology utilizing a subconjunctival implant), Belkin Vision's rapid, automated laser system for effective intraocular pressure reduction, and Sanoculis, which is advancing a novel surgical approach. The company also encompasses OphRx, focused on developing pharmaceutical treatments for ocular disorders; AEYE, which designs artificial intelligence-powered solutions for diverse retinal conditions; and Tarsier, working on TRS 01, a platform-based treatment for uveitis in patients with elevated intraocular pressure. Founded in 2005, the Tel Aviv, Israel-based company operated as Bio Light Israeli Life Sciences Investments Ltd. until its rebranding to BioLight Life Sciences Ltd. in February 2016.